Jennison Associates
SRPT icon

Jennison Associates’s Sarepta Therapeutics SRPT Stock Holding History

Jennison Associates’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-62,000
Closed -$10.6M – 737
2020
Q4 		$10.6M Buy
+62,000
New +$9.19M 0.01% 397
2016
Q3 		– Sell
-298,900
Closed -$5.7M – 683
2016
Q2 		$5.7M Buy
+298,900
New +$5.54M 0.01% 494

Other funds holding SRPT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Jennison Associates's SRPT Position: Q4 2023 in Review

Jennison Associates sold out of Sarepta Therapeutics (SRPT) in Q4 2023, closing a stake of 138,388 shares — an estimated $16.8M sold.

Jennison Associates first reported a position in SRPT in Q3 2014 and held it in 30 quarters. The position peaked at $414M in Q4 2020. 395 funds tracked by Wall St. Rank hold SRPT as of Q4 2023.

  • Jennison Associates reported no remaining Sarepta Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Jennison Associates sold 138,388 Sarepta Therapeutics shares in Q4 2023, an estimated $16.8M.
  • Jennison Associates first reported a position in Sarepta Therapeutics in Q3 2014 and held it in 30 quarters.
  • Jennison Associates's Sarepta Therapeutics position peaked at $414M in Q4 2020.
  • 395 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q4 2023.

Based on Jennison Associates's 13F filing for Q4 2023, filed 1 Feb 2024.